Inhaled salmeterol and fluticasone: a study comparing monotherapy and combination therapy in asthma

Citation
Ds. Pearlman et al., Inhaled salmeterol and fluticasone: a study comparing monotherapy and combination therapy in asthma, ANN ALLER A, 82(3), 1999, pp. 257-265
Citations number
28
Categorie Soggetti
Clinical Immunolgy & Infectious Disease
Journal title
ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY
ISSN journal
10811206 → ACNP
Volume
82
Issue
3
Year of publication
1999
Pages
257 - 265
Database
ISI
SICI code
1081-1206(199903)82:3<257:ISAFAS>2.0.ZU;2-Z
Abstract
Background: The current stepwise approach to pharmacotherapy in the treatme nt of asthma includes the initiation of an inhaled corticosteroid with the addition of a long-acting inhaled bronchodilator if low dose inhaled cortic osteroid fails to control asthma symptoms. Objective: To determine whether initiation of salmeterol and fluticasone pr opionate treatment together improves asthma control greater than initiation of monotherapy with the individual agents alone with no additional safety risk in patients with asthma who had not previously been treated with inhal ed corticosteroids. Methods: A total of 136 male and female patients at least 12 years of age w ith asthma [forced expiratory volume in 1 second (FEV1) between 50% and 80% of predicted] were randomized to twice daily salmeterol 42 mu g, fluticaso ne propionate 88 mu g, fluticasone propionate 220 mu g, salmeterol 42 mu g plus fluticasone propionate 88 mu g, salmeterol 42 mu g plus fluticasone pr opionate 220 mu g, or placebo for 4 weeks. Results: Patients treated with salmeterol combined with fluticasone propion ate had improvements over baseline in FEV1 at endpoint that were at least t wice as great (0.6 to 0.7 L) as improvements in patients treated with salme terol (0.3 L) or fluticasone propionate alone (0.3 L) (P < .05). Patient-ra ted data (peak expiratory flow, asthma symptom scores, percent of days with no asthma symptoms) confirmed greater (P < .05) mean change from baseline improvements after combined treatment compared with fluticasone propionate alone. No clinically significant differences were noted between treatment g roups in any safety measurement. Conclusion: Initiation of maintenance therapy with salmeterol and fluticaso ne propionate in patients with asthma treated with short-acting beta(2)-ago nists alone provides greater improvements in pulmonary function and symptom control than initiation of maintenance therapy with fluticasone propionate alone.